Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy
This work considers Phase I cancer dual-agent dose-escalation clinical trials in which one of the compounds is an immunotherapy. The distinguishing feature of trials considered is that the dose of one agent, referred to as a standard of care, is fixed and another agent is dose-escalated. Conventionally, the goal of …